Compare MDXH & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MDXH | IXHL |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | Belgium | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 42.1M |
| IPO Year | 2021 | 2024 |
| Metric | MDXH | IXHL |
|---|---|---|
| Price | $0.76 | $3.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $7.67 | N/A |
| AVG Volume (30 Days) | ★ 989.2K | 244.3K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.16 |
| 52 Week High | $5.33 | $6.39 |
| Indicator | MDXH | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 14.92 | 41.51 |
| Support Level | $0.68 | $0.33 |
| Resistance Level | $2.30 | $3.68 |
| Average True Range (ATR) | 0.11 | 0.30 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 5.32 | 20.62 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.